Department of Spine Surgery, Wuhan No. 1 Hospital, Wuhan, China.
Pain Physician. 2019 Jan;22(1):63-68.
To investigate the therapeutic effectiveness of percutaneous kyphoplasty (PKP) combined with zoledronic acid in treatment of primary osteoporotic vertebral compression fractures.
A perspective cohort study was conducted at a single institution for patients, who received PKP operation due to primary osteoporotic vertebral compression fracture between January 2014 and January 2015.
According to whether they received postoperative zoledronic acid or not, patients were divided into treatment or control groups, with 30 randomly-selected cases per group.
The visual analogue scale (VAS), which was used to assess the degree of pain, and the bone mineral density, was analyzed at 1-, 6-, and 12-month follow-ups.
In general, patients experienced marked pain relief after surgery. No significant difference in pain relief was observed in the control group between the 6 and 12-month follow-up. In contrast, the VAS score of the treatment group at 12-month follow-up was significantly lower than that at 6-month (P value = 0.03). Moreover, it was also significantly lower than the VAS score in the control group at the 12-month follow-up (P value = 0.0018). The bone mineral density of patients from the treatment group increased significantly and progressively after the surgery (pre-operation versus 6-month follow-up: P value = 0.01; 6-month versus 12-month follow-up: P value < 0.001), and it was also remarkably higher than that of the control group at the 12-month follow-up (P value < 0.0001).
Patients were collected from a single hospital. The maximum postoperative follow-up time was 12 months. The sample size was relatively small. Thus, bias could occur in the selection of cases if they are not representative of the population.
The combined treatment of zoledronic acid with PKP for primary osteoporotic vertebral compression fractures safely and effectively relieved low back pain, significantly increased bone density, and improved the quality of life. The clinical effectiveness is promising and worthy of further study.
Kyphoplasty, zoledronic acid, primary osteoporotic vertebral compression fractures.
探讨经皮椎体后凸成形术(PKP)联合唑来膦酸治疗原发性骨质疏松性椎体压缩骨折的疗效。
对 2014 年 1 月至 2015 年 1 月因原发性骨质疏松性椎体压缩骨折接受 PKP 手术的患者进行单中心前瞻性队列研究。
根据术后是否接受唑来膦酸治疗,将患者分为治疗组和对照组,每组 30 例。
采用视觉模拟评分(VAS)评估疼痛程度,分析骨密度在 1、6 和 12 个月随访时的变化。
一般来说,患者术后疼痛明显缓解。对照组在 6 个月和 12 个月随访时疼痛缓解无显著差异。相比之下,治疗组在 12 个月随访时的 VAS 评分明显低于 6 个月(P 值=0.03),且明显低于对照组在 12 个月随访时的 VAS 评分(P 值=0.0018)。治疗组患者的骨密度在手术后显著增加且逐渐增加(术前与 6 个月随访时:P 值=0.01;6 个月与 12 个月随访时:P 值<0.001),且在 12 个月随访时明显高于对照组(P 值<0.0001)。
患者来自单家医院。术后随访时间最长为 12 个月。样本量相对较小,如果病例选择不能代表人群,则可能存在选择偏倚。
PKP 联合唑来膦酸治疗原发性骨质疏松性椎体压缩骨折能安全有效地缓解腰痛,显著增加骨密度,提高生活质量。临床疗效令人期待,值得进一步研究。
椎体后凸成形术;唑来膦酸;原发性骨质疏松性椎体压缩骨折。